• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    US FDA Grants End of Phase 2 Meeting to OS Therapies

    BUSINESSWIRE

    OS Therapies Forms Subsidiary for Canine Osteosarcoma Therapy

    BUSINESSWIRE

    OS Therapies Secures U.S. Patent for OST-HER2 in Pediatric Cancer

    BUSINESSWIRE

    OS Therapies Reports Data for OST-HER2 in Unresected Osteosarcoma

    BUSINESSWIRE

    OS Therapies Acquires Advaxis Immuno Assets from Ayala Pharma

    BUSINESSWIRE

    OS Therapies Seeks FDA Meeting for OST-HER2 Approval

    BUSINESSWIRE

    OS Therapies to Host Analyst Day at NYSE on April 7, 2025

    BUSINESSWIRE

    OS Therapies Update on Rare Pediatric Cancer Immunotherapy OST-HER2

    BUSINESSWIRE

    OS Therapies Reports 2024 Financial Results and Business Update

    BUSINESSWIRE

    OS Therapies` OST-HER2 Immunotherapy in Movie Shelter

    BUSINESSWIRE

    OS Therapies Awarded OST-HER2 Trial Data Presentation at MIB Agent

    BUSINESSWIRE

    UK`s MHRA schedules 2025 meeting for OS Therapies` OST-HER2 revie

    BUSINESSWIRE

    OS Therapies To Host Live Investor Webinar & Q&A On Feb 27

    BUSINESSWIRE

    OS Therapies Launches Subsidiary OS Drug Conjugates, Strategic Options

    BUSINESSWIRE

    OS Therapies Gets U.S. Patent Allowance For OST-HER2 Manufacturing

    BUSINESSWIRE

    OS Therapies Starts OST-HER2 Manufacturing For BLA Filing

    BUSINESSWIRE

    OS Therapies Provides Corporate Update

    BUSINESSWIRE

    OS Therapies Acquires Ayala’s Listeria Immuno-Oncology Assets

    BUSINESSWIRE

    OS` drug stopped lung cancer from returning in 3rd of patients

    FIERCE BIOTECH

    OS Therapies to Attend 43rd Annual J.P. Morgan Conference

    BUSINESSWIRE

    OS Therapies Announces Closing of $6 Million Private Placement

    BUSINESSWIRE

    OS Therapy Partner with B2i Digital for Biotech Invest Engagement

    BUSINESSWIRE

    OS Therapies to Present at the LD Micro Main Event XVII

    BUSINESSWIRE

    OS Therapies Announces Development Of Novel Tunable ADC Candidates

    BUSINESSWIRE

    OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

    BUSINESSWIRE

    OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.